129 filings
Page 5 of 7
S-3ASR
0d25 vxv5j9icv7bd
3 Sep 21
Automatic shelf registration
4:22pm
8-K
p2gx4lc
9 Aug 21
Inhibrx Reports Second Quarter 2021 Financial Results
4:12pm
8-K
pbimowb9ff
21 Jun 21
Entry into a Material Definitive Agreement
4:05pm
8-K
6adwfcu83m
9 Jun 21
Submission of Matters to a Vote of Security Holders
12:00am
8-K
cv3aaj8k2chkp lcmel
13 May 21
Inhibrx Reports First Quarter 2021 Financial Results
4:05pm
DEFA14A
p301zfmg
28 Apr 21
Additional proxy soliciting materials
7:53am
DEF 14A
we9h 6kym5
28 Apr 21
Definitive proxy
7:51am
8-K
75pkh7qzdddxc r4
12 Mar 21
Results of Operations and Financial Condition
8:55am
10-K
385dz2hs8w eefjm7
12 Mar 21
Annual report
8:46am
S-8
xj6h68b6n90ca13f34
19 Jan 21
Registration of securities for employees
4:06pm
8-K
uh8pl 828d
13 Jan 21
Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients
9:03am
8-K
1puu4kv
5 Jan 21
Inhibrx Announces Phase 1 Dose Escalation Results of
12:00am
8-K
2yruqyy0bn
13 Nov 20
Inhibrx Reports Financial Results for the Third Quarter 2020 and Announces Amended Loan Agreement with Oxford
4:13pm
10-Q
l3b3gcy9 pbtkgernq
13 Nov 20
Quarterly report
4:09pm
8-K
ssbecm oxj4nu8me8gp
12 Nov 20
Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients
6:07am
8-K
bt01hk7vmv6x
11 Sep 20
Regulation FD Disclosure
4:24pm
8-K
omkfyf1s
21 Aug 20
Unregistered Sales of Equity Securities
4:19pm
S-8
ut9r5lalfz mmt95
19 Aug 20
Registration of securities for employees
5:27pm